Amneal Pharmaceuticals (AMRX) Retained Earnings (2017 - 2026)

Amneal Pharmaceuticals' Retained Earnings history runs 10 years deep, the most recent figure standing at $536.3 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 725.49% year-over-year to $536.3 million in Q1 2026; TTM through Mar 2026 was $536.3 million, a 725.49% increase from a year earlier, with the FY2025 full-year figure at -$535.0 million, up 11.87% from the prior year.
• Retained Earnings grew to $536.3 million in Q1 2026 per AMRX's latest filing, from -$535.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at $700.7 million in Q1 2023 and bottomed at -$607.1 million in Q4 2024.
• The 5-year median for Retained Earnings is -$23.7 million (2024), against an average of -$10.5 million.
• Across the five-year window, Retained Earnings soared 200879.94% in 2023 and plunged 7223.9% in 2024, its largest moves.
• Year by year, Retained Earnings stood at $9.9 million in 2022, then tumbled by 425.48% to -$32.3 million in 2023, then slumped by 1776.6% to -$607.1 million in 2024, then grew by 11.87% to -$535.0 million in 2025, then soared by 200.24% to $536.3 million in 2026.
• Per Business Quant, the three latest AMRX Retained Earnings figures stand at $536.3 million (Q1 2026), -$535.0 million (Q4 2025), and $563.4 million (Q3 2025).